Gene: SHKBP1
Official Full Name: SH3KBP1 binding protein 1provided by HGNC
Gene Summary: Enables identical protein binding activity. Predicted to be involved in positive regulation of epidermal growth factor receptor signaling pathway. Predicted to be located in lysosome. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO04359 | SHKBP1 Knockout cell line (HeLa) | Human | SHKBP1 | 1:3~1:6 | Negative | Online Inquiry |
KO04360 | SHKBP1 Knockout cell line (HCT 116) | Human | SHKBP1 | 1:2~1:4 | Negative | Online Inquiry |
KO04361 | SHKBP1 Knockout cell line (HEK293) | Human | SHKBP1 | 1:3~1:6 | Negative | Online Inquiry |
KO04362 | SHKBP1 Knockout cell line (A549) | Human | SHKBP1 | 1:3~1:4 | Negative | Online Inquiry |
SHKBP1 Gene Knockout Cell Lines are specialized cell lines engineered to disrupt the SHKBP1 gene, which encodes a protein implicated in various cellular processes, including signaling pathways involved in cell proliferation and differentiation. These knockout cell lines serve as powerful tools for investigating the function of SHKBP1 in both normal physiological states and pathological conditions, thereby allowing researchers to explore the intricate dynamics of cellular behavior in a controlled environment.
The key function of SHKBP1 Gene Knockout Cell Lines is their ability to facilitate the understanding of SHKBP1's role in critical signaling cascades, particularly those related to cancer biology and cellular stress responses. By effectively eliminating the expression of the SHKBP1 gene, researchers can observe alterations in cellular functions, enabling insights into mechanisms of tumorigenesis, response to therapeutic interventions, and other biological phenomena. Furthermore, these cell lines are invaluable for the validation of drug targets and the assessment of new therapeutic strategies.
From a scientific standpoint, the applications of SHKBP1 Gene Knockout Cell Lines in research settings are extensive. They provide a unique model for studying diseases such as cancer and neurodegenerative disorders, where SHKBP1 is suspected to play a significant role. In clinical settings, these cell lines could lead to potential biomarker discoveries and the development of novel therapeutic strategies targeting specific pathways regulated by the SHKBP1 protein.
Among the key advantages of using SHKBP1 Gene Knockout Cell Lines are their high specificity and reproducibility, which surpass many traditional methods of gene knockdown, such as RNA interference. This specificity allows for clear interpretations of experimental outcomes and minimizes off-target effects that often complicate data analysis in other systems. Additionally, the ease of integration into various experimental workflows positions these cell lines as a versatile asset in the laboratory.
For researchers and clinicians focused on cellular pathways and their implications in health and disease, SHKBP1 Gene Knockout Cell Lines represent an invaluable resource, offering clarity and depth to studies aimed at elucidating the complexities of gene function. Our company prides itself on its commitment to advancing research through innovative products like these cell lines, supported by a team of experts dedicated to providing outstanding scientific solutions.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.